Bank of New York Mellon’s Benitec Biopharma BNTC Stock Holding History

Bank of New York Mellon’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$804K	Buy	60,061 +16,572	+38%	+$197K	﹤0.01%	3487
2026 Q1	$463K	Buy	43,489 +11,877	+38%	+$138K	﹤0.01%	3647
2025 Q4	$426K	Sell	31,612 -2,389	-7%	-$33K	﹤0.01%	3693
2025 Q3	$477K	Buy	34,001 +2,050	+6%	+$26.2K	﹤0.01%	3621
2025 Q2	$374K	Buy	+31,951	New	+$447K	﹤0.01%	3671
2022 Q4	–	Sell	-872	Closed	-$6K	–	4472
2022 Q3	$6K	Hold	872	–	–	﹤0.01%	4527
2022 Q2	$17K	Sell	872 -6	-0.7%	-$140	﹤0.01%	4508
2022 Q1	$35K	Hold	878	–	–	﹤0.01%	4567
2021 Q4	$39K	Hold	878	–	–	﹤0.01%	4530
2021 Q3	$53K	Hold	878	–	–	﹤0.01%	4429
2021 Q2	$63K	Sell	878 -160	-15%	-$12.5K	﹤0.01%	4293
2021 Q1	$91K	Buy	+1,038	New	+$70.6K	﹤0.01%	4176

Other funds holding BNTC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

PAP

Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Bank of New York Mellon's BNTC Position: Q2 2026 in Review

Bank of New York Mellon increased its Benitec Biopharma (BNTC) stake by 38% in Q2 2026, buying an estimated $197K and bringing the position to 60,061 shares worth $804K. The position accounts for ﹤0.01% of the portfolio, ranked #3487.

Bank of New York Mellon first reported a position in BNTC in Q1 2021 and has held it in 12 quarters since. 26 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

Bank of New York Mellon held 60,061 shares of Benitec Biopharma worth $804K as of Q2 2026.
Bank of New York Mellon bought 16,572 Benitec Biopharma shares in Q2 2026, an estimated $197K.
Benitec Biopharma made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3487 holding.
Bank of New York Mellon first reported a position in Benitec Biopharma in Q1 2021 and has held it in 12 quarters since.
26 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.